| Pharmaceutical Information |
| Drug Name |
Interferon gamma-1b |
| Drug ID |
BADD_D01171 |
| Description |
Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography.
The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b. |
| Indications and Usage |
Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB00033
|
| KEGG ID |
D00747
|
| MeSH ID |
C554125
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0U9EN
|
| NDC Product Code |
17089-378; 75987-111 |
| UNII |
21K6M2I7AG
|
| Synonyms |
interferon gamma-1b | interferon gamma-2a | Actimmune |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
98059-61-1 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
